Combined use of nanobody, cyclodextrin and quercetin for protection from enveloped viruses

carbohydrates, ,

Fascinating antiviral application of cyclodextrins against SARS-COV2. You can find specific nanobodies against different target antigens such as the spike protein of the SARS-CoV-2 virus and or to the ACE2 receptor at the host cell surface, binds to the virus or the ACE2 receptor at the host cell plasma membrane, preventing entry of the SARS-CoV-2 virus. The nanobodies comprise a cyclodextrin; a zinc ionophore; a zinc-containing compound; and, benzalkonium.

WO2024035526 COMBINED USE OF NANOBODY, CYCLODEXTRIN AND QUERCETIN FOR PROTECTION FROM ENVELOPED VIRUSES (wipo.int)

Hydrogel composition for use in the treatment of articular disorders

carbohydrates, drug development,

Fascinating patent by Bernard Martel, Nicolas Blanchemain and colleagues presenting hydrogels on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. The hydrogel combines an analgesic action with a visco-supplementation (a lubricating effect).

WO2024023350 HYDROGEL COMPOSITION FOR USE IN THE TREATMENT OF ARTICULAR DISORDERS (wipo.int)

Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption

Today's cyclodextrin, , ,

Today’s cyclodextrin research highlights a promising new therapy for inflammation-related diseases and oxidative damage. Researchers have presented a new anti-inflammatory and antioxidant nanoparticle, LCD, which aims to protect against severe burn-induced intestinal injury. With traditional methods showing limitations, the application of nanoparticles like LCD could offer a much-needed protective strategy for the intestinal barrier.

Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption | Burns & Trauma | Oxford Academic (oup.com)


#burninjury #inflammation #antioxidant #nanotechnology

Resveratrol eye drops as well as preparation method and application

drug development, ,

In some cases, the simplest, most straightforward ideas are the best. Why not develop an eye-drop based on cyclodextrin and resveratrol?  The resveratrol captured in an HPBCD inclusion complex has the advantages of simple preparation, short preparation period, no organic solvent residue, and no bacteriostatic agent. The lipoic acid added in the clathrate eye drops prepared by the invention cooperates with the resveratrol to play a better antioxidant effect so that the xerophthalmia is better relieved, and the treatment effect is achieved.

What to create similar solutions? Visit: www.carbohydesolutions.com – Carbohyde
Original paper: Espacenet – Resveratrol eye drops as well as preparation method and application thereof

Pharmaceutical composition and application patent

Today's cyclodextrin, ,

Today’s cyclodextrin is an interesting application proposed by RemeGen Biosciences, which uses methyl-BCD to remarkably improve the pharmaceutical effect of antibody-drug conjugates. By using CDs, the ACD load can be lower, thus greatly reducing the production cost and the treatment cost of a patient.
If you are interested in similar solutions, check out Formulation development – www.carbohydesolutions.com

Espacenet – Pharmaceutical composition and application thereof

Synthesis and Preliminary Evaluation of an ASGPr-Targeted Polycationic β-Cyclodextrin Carrier for Nucleosides and Nucleotides

drug delivery, , ,

As our interest to use cyclodextrin in genetherapy as superior drugdelivery tools continue, we welcome papers like this, where cationic CD polymers are used for nucleotide formulation.
Leonard Wiebe and coworkers from University of Alberta development a carrier designed to effect selective transmembrane internalization of nucleotides via the asialoglycoprotein receptor.

Pharmaceutics | Free Full-Text | Synthesis and Preliminary Evaluation of an ASGPr-Targeted Polycationic β-Cyclodextrin Carrier for Nucleosides and Nucleotides (mdpi.com)


Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study

carbohydrates,

Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study

In this work form University of Southern California blocking viral attachment and entry at the nasal airway using a cyclodextrin-based formulation is presented, so that a preventative therapy can be developed to reduce viral infection at the site of entry. After screening several CDs, hydroxypropyl beta-cyclodextrin (HPBCD) and hydroxypropyl gamma-cyclodextrin (HPGCD) were then further evaluated for antiviral effects using SARS-CoV-2 pseudotypes. Intranasal pre-treatment with HPBCD-based formulations reduced viral load and inflammatory signaling in the lung.

In vitro efficacy studies were further conducted using lentiviruses, murine hepatitis virus (MHV), and influenza A virus subtype H1N1. These findings suggest HPBCD may be used as an agnostic barrier against transmissible pathogens, including but not limited to SARS-CoV-2.

IJMS | Free Full-Text | Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study (mdpi.com)

New cyclodextrin dimer patent!

Today's cyclodextrin,

today’s cyclodextrin:
I am proud to share this new patent from Cyclarity Therapeutics not only because of the fantastic chemistry and excellent drug development but also as CarboHyde CSO Milo Malanga is among the inventors!

Cyclodextrin dimers are used to target 7-ketocholesterol, eventually to reverse atherosclerotic plaques.
Check out for more info: Espacenet – US2024043661A1

Congratulation to Milo and the geat team at Cyclarity!

Oral alpha-cyclodextrin reverses cholesterol-crystal-induced retinal pathology in a rodent model of type 2 diabetes

Today's cyclodextrin, ,

Today’s cyclodextrin a study showing how alpha-CD treatment could be used in type-2 diabetes patients.
Cholesterol crystals were eliminated from the retinas of diabetic mice after oral alpha-cyclodextrin treatment. These findings demonstrate that T2D is associated with cholesterol crystal-induced retinal pathology that is improved using oral alpha-cyclodextrin. Improvements were observed in inflammation, neural function and visual response.

Oral alpha-cyclodextrin reverses cholesterol-crystal-induced retinal pathology in a rodent model of type 2 diabetes (T2D). | IOVS | ARVO Journals

New Captisol (Ligand Pharmaceuticals) enabled API on the market!

drug delivery, Today's cyclodextrin,

Today’s cyclodextrin:

Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol®, a Ligand technology.

About perampanel (Fycompa®)
Perampanel is a first-in-class anti-epileptic agent (AED) discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is currently approved in more than 75 countries and territories, including Japan, China, and other countries in Europe and Asia, as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. In addition, perampanel has been approved in more than 70 countries, including Japan, Europe, and Asia, for treatment as an adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In Japan and China, perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older. In Europe, the approved age range is 4 years of age and older for the adjunctive treatment of partial-onset seizures (with or without secondarily generalized seizures) and 7 years of age and older for the treatment as an adjunctive therapy for primary generalized tonic-clonic seizure. A tablet, fine granule formulation, and injection formulation have been approved in Japan. An oral suspension formulation and tablet have been approved in Europe and China. In January 2023, the commercial rights in the United States were transferred to Catalyst Pharmaceuticals, Inc.